David Charles Baker - 15 Feb 2022 Form 4 Insider Report for Vallon Pharmaceuticals, Inc. (GRI)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GRI	Stock Option (Right to Buy)	Award	$343,430	+61,000		$5.63	61,000	15 Feb 2022	Common Stock	61,000	$5.63	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Reported late due to administrative error.
F2	Vests as to 25% of the underlying shares of common stock on the first annual anniversary of the date of grant, then in 12 equal quarterly installments such that the stock option is fully vested on the fourth annual anniversary of the date of grant.